Cantor Fitzgerald Reiterates Overweight on Longboard Pharmaceuticals, Maintains $90 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Josh Schimmer has reiterated an Overweight rating on Longboard Pharmaceuticals (NASDAQ:LBPH) and maintained a $90 price target.
September 16, 2024 | 3:56 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald has reiterated an Overweight rating for Longboard Pharmaceuticals, maintaining a $90 price target, indicating confidence in the company's potential.
The reiteration of an Overweight rating and a high price target by a reputable analyst suggests positive sentiment and potential upside for LBPH, likely boosting investor confidence and short-term stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100